First Oral Option for Dermatomyositis Gets FDA Green Light

Roivant Sciences Wins FDA Approval for LISRAYA in Dermatomyositis, Launches Immediately

Roivant Sciences (NASDAQ:ROIV) said the U.S. Food and Drug Administration has approved LISRAYA, its once-daily oral therapy for adults with dermatomyositis, and that the drug has already entered commercial launch. Matt Gline, Roivant’s CEO, called the approval a significant milestone for patients w

Roivant wins FDA approval for first targeted dermatomyositis treatment

Roviant & Priovant Therapeutics finally secure US approval for once-daily oral TYK2/JAK1 inhibitor, Lisraya (brepocitinib), for dermatomyositis.

Pfizer-backed Priovant wins FDA nod for lead drug (ROIV:NASDAQ)

Pfizer (PFE)- and Roivant Sciences (ROIV)-backed Priovant wins FDA approval for Lisraya in dermatomyositis, a rare autoimmune disorder. Read more here.

FDA green lights Priovant drug for rare skin disease

Lisraya’s clearance marks the first approval of a drug the Roivant subsidiary licensed from Pfizer and has since positioned against multiple rare inflammatory conditions.

A Once Daily Pill Becomes the First Approved Treatment for Dermatomyositis After Decades of Borrowed Therapies

FDA approved Lisraya (brepocitinib), the first oral drug indicated for dermatomyositis. Here is the trial evidence, the boxed warning, and the cost.

First Oral Option for Dermatomyositis Gets FDA Green Light

(MedPage Today) -- The FDA approved the first oral treatment option for the autoimmune disorder dermatomyositis. Brepocitinib (Lisraya) is indicated for adults with the rare condition, which causes chronic inflammation, progressive muscle weakness...